お知らせ • Jun 16
Creative Medical Technology Holdings Advances Project Phoenix into Nationwide Ai Driven Virtual Data Collection Phase for U.S. Veterans Exposed to Burn Pits and Toxic Hazards
Creative Medical Technology Holdings, Inc. announced the next operational milestone in Project PHOENIX, the Company's regulatory-approved, proprietary AI-driven registry and CELZ-Biodefense Regenerative BioDefense Initiative designed to support U.S. veterans exposed to burn pits, toxic environmental hazards and related service-connected exposure risks. The regulatory approved CELZ-Biodefense platform is designed to scale to at least 1,000 veterans through AI-enabled mobile-app data collection and field-capable logistics. The platform is designed to support an initial cohort of at least 1,000 veterans across the United States and to create a scalable foundation for future exposed military and civilian populations. The decentralized model is designed to enable eligible veterans to participate from anywhere in the United States through a virtual mobile-app data collection system that captures exposure history, symptom patterns, patient-reported outcomes, longitudinal health information and other relevant data. When biospecimen collection or additional in-person data capture is required, CELZ's field-capable workflow is designed so trained collection teams can coordinate locally with participating veterans, reducing or eliminating the need for veterans to travel to centralized research sites. The platform is designed to compare multi-omics signatures from exposed veterans against non-exposed reference populations. By applying AI-driven interpretation algorithms to these exposed-versus-non-exposed datasets, CELZ aims to identify biomarkers, exposure-associated disease pathways, risk signatures and potential therapeutic targets that may support the development of targeted drugs, biologics, biotherapeutics, regenerative cell therapies and other precision interventions for veterans and future exposed patients. The Company believes this model can create multiple strategic outputs: A scalable, AI-ready dataset linking exposure history, clinical status and molecular biology. Biomarker and pathway insights that may help stratify toxic exposure-related disease risk and progression. iPSC-based disease and cellular injury models to support mechanistic research and therapeutic screening. Potential drug, biologic, biotherapeutic and regenerative therapy targets for future internal development or collaboration. A flexible Regenerative BioDefense framework that may be extended to environmental, industrial, chemical, biological and other emerging exposure threats. As participation grows and data accrues, CELZ is developing the CELZ-Biodefense Toxic Exposure Atlas™, a proprietary AI-enabled discovery asset intended to organize exposure history, clinical outcomes, longitudinal participant data, multi-omics signatures, cellular-response data and disease biology into an interpretable framework. The Atlas is intended to enable CELZ research teams and potential future partners to accelerate drug, biologic, biotherapeutic and regenerative therapeutic discovery by identifying patterns that may otherwise remain hidden in fragmented or siloed datasets. CELZ believes the Atlas can become a foundational, partner-ready asset for Regenerative BioDefense by connecting exposure characterization directly to target discovery, candidate prioritization and iPSC-based disease modeling. The Company expects the CELZ-Biodefense Toxic Exposure Atlas™ to support: Identification of molecular signatures associated with burn pit and toxic exposure. Comparison of exposed veteran cohorts with non-exposed reference populations. Stratification of participants by molecular risk profiles and disease progression patterns. Discovery of biomarkers linked to respiratory, cardiovascular, neurological, inflammatory, immune-mediated and systemic effects. AI-driven target discovery for drugs, biologics, biotherapeutics and regenerative therapies. Creation of iPSC-based models to study exposure-related injury pathways and screen therapeutic approaches. Expansion into future military, civilian, environmental, industrial, chemical and biological exposure applications.